Lysosomal storage diseases: Stem cell-based cell- and gene-therapy

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Lysosomal storage diseases (LSDs) stem from genetic enzyme deficiencies, causing substrate accumulation and cellular dysfunction, particularly in the central nervous system (CNS).
• Current treatments like enzyme replacement therapy (ERT) and cell transplantation have limitations, including the inability to cross the blood-brain barrier (BBB) and limited efficacy in certain LSDs.
• The BBB prevents enzyme preparations from reaching the brain, hindering effective treatment for CNS pathology in most LSDs.

Purpose of the Study:

• To explore stem cell-based gene therapy as a potential treatment for LSDs by overcoming the BBB.
• To evaluate the efficacy of genetically modified neural stem cells for delivering therapeutic enzymes to the CNS in LSD models.

Main Methods:

• Utilizing genetically modified neural stem cells engineered to encode specific enzyme genes.
• Administering these modified stem cells via intracranial transplantation to target CNS lesions.
• Assessing the reduction of lysosomal storage, neuropathology, and survival rates in animal models of LSDs.

Main Results:

• Genetically modified neural stem cells effectively delivered enzymes to the CNS, bypassing the BBB.
• Treatment led to decreased lysosomal storage and reduced neuropathology in mouse models of LSDs.
• Stem cell-based gene therapy significantly extended the lifespan of treated animals.

Conclusions:

• Stem cell-based gene therapy represents a highly effective strategy for treating LSDs affecting the CNS.
• This approach bridges the gap between ERT and traditional gene therapy, offering a promising future direction.
• Intracranial transplantation of genetically modified stem cells shows potential for sustained enzyme delivery and therapeutic benefit in LSDs.